Regulatory approval
Published by the Health Canada. Approved
TECENTRIQ (atezolizumab, concentrate for solution for infusion) is indicated as monotherapy, for the first-line treatment of patients with metastatic NSCLC whose tumours have high PD-L1 expression (PD-L1 stained >= 50% of TCs or PD-L1 stained tumour-infiltrating immune cells [ICs] covering >= 10% of the tumour area), as determined by a validated test and who do not have EGFR or ALK genomic tumour aberrations.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | PD-L1 >= 50%, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Atezolizumab | |
| HC (1) | PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Atezolizumab |